COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #202 of 260
11/30 Late treatment study
Abdulrahman et al., medRxiv, doi:10.1101/2020.11.25.20234914 (Preprint)
The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort
Source   PDF   Share   Tweet
Retrospective medical record analysis of acute care patients in Bahrain not showing a significant effect of HCQ.
Confounding by indication is likely. Matching appears not to have matched for baseline severity - 17.5% of HCQ patients required oxygen while only 12.6% of control patients did.

Abdulrahman et al., 11/30/2020, retrospective, Bahrain, Middle East, preprint, 9 authors.
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 5 of 223 (2.2%), control 6 of 223 (2.7%), PSM.
risk of combined intubation/death, 75.0% higher, RR 1.75, p = 0.24, treatment 12 of 223 (5.4%), control 7 of 223 (3.1%), adjusted per study, PSM.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit